Tarsus director granted RSUs and stock options

Tarsus Pharmaceuticals director David E.I.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director David E.I. Pyott received new equity awards tied to his service as a non-employee director at the company’s 2026 annual meeting of stockholders. The grants are compensation awards, not open-market purchases or sales.

He was granted 806 restricted stock units (RSUs) and an additional 2,417 RSUs, each representing one share of common stock. One RSU grant vests in full on the one-year anniversary of the June 25, 2026 grant date, while the other vests in four equal installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027, in each case subject to his continuous service.

Pyott also received a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share, expiring on June 24, 2036. This annual option grant will vest in full on the one-year anniversary of the grant date, contingent on his continued service as a non-employee director.

Insider Trade Summary

Grant/Award: 7,060 shares

Grant/Award 3 txns

Insider PYOTT DAVID E I

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,837	$0.00	$0.00
Grant/Award	Restricted Stock Units	2,417	$0.00	$0.00
Grant/Award	Restricted Stock Units	806	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 3,837 contracts (Direct); Restricted Stock Units — 3,223 contracts (Direct)

Footnotes (4)

1. F1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
4. F4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Key Figures

RSU grant 1: 806 RSUs RSU grant 2: 2,417 RSUs Stock option size: 3,837 shares +2 more

5 metrics

RSU grant 1 806 RSUs Granted June 25, 2026; vests in full one year after grant, subject to continuous service

RSU grant 2 2,417 RSUs Granted June 25, 2026; vests in four installments from September 2026 to June 2027

Stock option size 3,837 shares Annual option grant to non-employee director on June 25, 2026

Option exercise price $64.34 per share Conversion or exercise price for the 3,837-share stock option grant

Option expiration June 24, 2036 Expiration date of the stock option granted to the director

Key Terms

Restricted Stock Unit ("RSU"), Stock Option (right to buy), non-employee director, continuous service, +1 more

5 terms

Restricted Stock Unit ("RSU") financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $64.34 per share"

non-employee director financial

"service as a non-employee director as of the Company's 2026 annual meeting"

continuous service financial

"subject to the non-employee director's continuous service"

annual meeting of stockholders financial

"as of the Company's 2026 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Tarsus (TARS) director David Pyott receive?

David E.I. Pyott received 806 RSUs, 2,417 additional RSUs, and a stock option for 3,837 shares at an exercise price of $64.34. These awards are part of his compensation for serving as a non-employee director.

Are David Pyott’s new Tarsus (TARS) awards open-market share purchases?

No, the Form 4 shows compensation-related grants, not market trades. The RSUs and stock option were awarded in connection with his service as a non-employee director at Tarsus’s 2026 annual meeting of stockholders.

How do the RSUs granted to Tarsus (TARS) director David Pyott vest?

One RSU grant vests in full one year after the June 25, 2026 grant date. The other vests in four equal installments on 9/15/2026, 12/15/2026, 3/15/2027, and 6/15/2027, all subject to his continuous service as a non-employee director.

What are the terms of David Pyott’s Tarsus (TARS) stock option grant?

The stock option covers 3,837 shares of Tarsus common stock at an exercise price of $64.34 per share and expires on June 24, 2036. It will vest in full on the one-year anniversary of the grant date, contingent on his continued board service.

Why did Tarsus (TARS) grant RSUs and options to David Pyott?

The RSUs and stock option were granted as annual equity compensation for Pyott’s role as a non-employee director as of Tarsus’s 2026 annual meeting. Such awards align director incentives with shareholder interests through long-term equity-based compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PYOTT DAVID E I

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS

17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$64.34	06/25/2026		A		3,837		(1)	06/24/2036	Common Stock	3,837	$0	3,837	D
Restricted Stock Units	(2)	06/25/2026		A		2,417		(3)	(3)	Common Stock	2,417	$0	2,417	D
Restricted Stock Units	(2)	06/25/2026		A		806		(4)	(4)	Common Stock	806	$0	806	D

Explanation of Responses:

1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Remarks:

	/s/ Scott Sieckert, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)